Keywords: Charles River, Vital River, Majority stake, Research models and services, China
Charles River Labs to buy majority stake in China's Vital River
Article | 31 October 2012
USA-based Charles River Laboratories International (NYSE:CRL) has entered into an agreement to acquire 75% ownership of Vital River, a leading ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
